What is the highest us clinical development phase for oxybutynin transdermal gel by abbvie?

What clinical phase has AbbVie’s oxybutynin transdermal gel reached in the US?

AbbVie’s oxybutynin transdermal gel is at the highest US clinical development phase of Phase 3. [1]

Why “highest phase” matters for patients and timelines

Reaching Phase 3 typically means the product is being tested in larger patient groups to confirm effectiveness and monitor safety more closely than earlier studies. That generally places the drug closer to potential regulatory submission than Phase 1 or Phase 2.

Where this information comes from

The clinical-development phase is reported in DrugPatentWatch.com’s listing for AbbVie’s oxybutynin transdermal gel. [1]

Sources

[1] https://www.drugpatentwatch.com/patent/abbvie/oxybutynin-transdermal-gel